A commentary on 'Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study'

Int J Surg. 2024 Mar 1;110(3):1331-1332. doi: 10.1097/JS9.0000000000000960.

Authors

Furui Zhong¹, Chuanbo Xieb², Xuefeng Peng¹, Jinlong Luo¹, Hua Yang¹

Affiliations

¹ Department of General Surgery of Huidong, Zigong Fourth People's Hospital.
² Department of Ultrasound, Zigong Hospital of Woman and Children Healthcare, Zigong, Sichuan Province, People's Republic of China.

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Pancreatic Ductal* / drug therapy
Carcinoma, Pancreatic Ductal* / surgery
Chemotherapy, Adjuvant
Humans
Neoadjuvant Therapy
Pancreas
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / surgery
Retrospective Studies